Literature DB >> 24190449

Influence of HbA1c on short-term blood pressure variability in type 2 diabetic patients with diabetic nephropathy.

Fang Liu1, Min Wu, Yan-huan Feng, Hui Zhong, Tian-lei Cui, You-qun Huang, Ya-ping Liang, Yong-shu Diao, Li Zang, Ling Li, Jing Zang, Hong-yu Qiu, Song-min Huang, Ping Fu.   

Abstract

The aim of this study was to understand the characteristics of blood pressure (BP) variability in subjects with diabetic nephropathy (DN), and identify the probable predictors affecting BP variability. Fifty-one chronic kidney disease (CKD)-hypertensive patients without diabetes (NDN group) and sixty type 2 diabetic patients with overt DN (DN group) were enrolled in this study. The values of short-term BP variability were obtained from 24 h ambulatory BP monitoring (ABPM). Variance analysis or nonparametric analysis revealed that 24-h systolic BP variability and nighttime systolic BP variability of the DN group were significantly higher than those of the NDN group [(12.23±3.66) vs. (10.74±3.83) mmHg, P<0.05; (11.23±4.82) vs. (9.48±3.69) mmHg, P<0.05]. Then the patients of the DN group were divided into two groups according to glycated hemoglobin (HbA1c) level: Group A (HbA1c<7%) and Group B (HbA1c≥7%), and the t-test showed that patients in Group B had larger 24-h diastolic, daytime diastolic, and nighttime systolic/diastolic BP variability compared with Group A. In the DN group, partial correlation analysis revealed that HbA1c exhibited a strong association with 24-h diastolic, daytime diastolic, nighttime systolic and diastolic BP variability (P<0.001, P<0.001, P<0.05, and P<0.001, respectively). Taken together, larger short-term BP variability was detected in hypertensive type 2 diabetic patients with overt nephropathy and renal insufficiency. It may imply that the optimal BP variability level could benefit from a better glycaemic control.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24190449      PMCID: PMC3829652          DOI: 10.1631/jzus.B1300030

Source DB:  PubMed          Journal:  J Zhejiang Univ Sci B        ISSN: 1673-1581            Impact factor:   3.066


  26 in total

1.  Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.

Authors:  David M Nathan; Patricia A Cleary; Jye-Yu C Backlund; Saul M Genuth; John M Lachin; Trevor J Orchard; Philip Raskin; Bernard Zinman
Journal:  N Engl J Med       Date:  2005-12-22       Impact factor: 91.245

Review 2.  Neural cardiovascular regulation and 24-hour blood pressure and heart rate variability.

Authors:  G Parati; M Di Rienzo; G Mancia
Journal:  Ann N Y Acad Sci       Date:  1996-08-15       Impact factor: 5.691

3.  Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).

Authors:  Amanda I Adler; Richard J Stevens; Sue E Manley; Rudy W Bilous; Carole A Cull; Rury R Holman
Journal:  Kidney Int       Date:  2003-01       Impact factor: 10.612

4.  Relationship of 24-hour blood pressure mean and variability to severity of target-organ damage in hypertension.

Authors:  G Parati; G Pomidossi; F Albini; D Malaspina; G Mancia
Journal:  J Hypertens       Date:  1987-02       Impact factor: 4.844

5.  A possible relationship of nocturnal blood pressure variability with coronary artery disease in diabetic nephropathy.

Authors:  Kouichi Tamura; Yuko Tsurumi; Masashi Sakai; Yutaka Tanaka; Yasuko Okano; Junji Yamauchi; Tomoaki Ishigami; Minoru Kihara; Nobuhito Hirawa; Yoshiyuki Toya; Machiko Yabana; Yasuo Tokita; Toshimasa Ohnishi; Satoshi Umemura
Journal:  Clin Exp Hypertens       Date:  2007-01       Impact factor: 1.749

6.  Glycaemic control and incidence of heart failure in 20,985 patients with type 1 diabetes: an observational study.

Authors:  Marcus Lind; Ioannis Bounias; Marita Olsson; Soffia Gudbjörnsdottir; Ann-Marie Svensson; Annika Rosengren
Journal:  Lancet       Date:  2011-06-24       Impact factor: 79.321

7.  Long-term effects of intensive glucose lowering on cardiovascular outcomes.

Authors:  Hertzel C Gerstein; Michael E Miller; Saul Genuth; Faramarz Ismail-Beigi; John B Buse; David C Goff; Jeffrey L Probstfield; William C Cushman; Henry N Ginsberg; J Thomas Bigger; Richard H Grimm; Robert P Byington; Yves D Rosenberg; William T Friedewald
Journal:  N Engl J Med       Date:  2011-03-03       Impact factor: 91.245

8.  Usefulness of home blood pressure measurement in the morning in type 2 diabetic patients.

Authors:  Kyuzi Kamoi; Masashi Miyakoshi; Satoshi Soda; Susumu Kaneko; Osamu Nakagawa
Journal:  Diabetes Care       Date:  2002-12       Impact factor: 19.112

9.  Glycemic control and cardiovascular disease in 7,454 patients with type 1 diabetes: an observational study from the Swedish National Diabetes Register (NDR).

Authors:  Katarina Eeg-Olofsson; Jan Cederholm; Peter M Nilsson; Björn Zethelius; Ann-Marie Svensson; Soffia Gudbjörnsdóttir; Björn Eliasson
Journal:  Diabetes Care       Date:  2010-04-27       Impact factor: 19.112

10.  Dysglycemia induces abnormal circadian blood pressure variability.

Authors:  Sivarajan Kumarasamy; Kathirvel Gopalakrishnan; Dong Hyun Kim; Nader G Abraham; William D Johnson; Bina Joe; Alok K Gupta
Journal:  Cardiovasc Diabetol       Date:  2011-11-22       Impact factor: 9.951

View more
  3 in total

1.  Within-visit blood pressure variability is associated with prediabetes and diabetes.

Authors:  Rieko Okada; Yoshinari Yasuda; Kazuyo Tsushita; Kenji Wakai; Nobuyuki Hamajima; Seiichi Matsuo
Journal:  Sci Rep       Date:  2015-01-15       Impact factor: 4.379

2.  Hemoglobin A1c is associated with severity of coronary artery stenosis but not with long term clinical outcomes in diabetic and nondiabetic patients with acute myocardial infarction undergoing primary angioplasty.

Authors:  Jianqing She; Yangyang Deng; Yue Wu; Yulong Xia; Hongbing Li; Xiao Liang; Rui Shi; Zuyi Yuan
Journal:  Cardiovasc Diabetol       Date:  2017-08-08       Impact factor: 9.951

3.  Improvement in Glycemic and Lipid Profiles in Type 2 Diabetics with a 90-Day Ketogenic Diet.

Authors:  Chase M Walton; Katelyn Perry; Richard H Hart; Steven L Berry; Benjamin T Bikman
Journal:  J Diabetes Res       Date:  2019-08-14       Impact factor: 4.011

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.